翰宇药业醋酸格拉替雷注射液获得美国FDA批准

Core Viewpoint - Hanyu Pharmaceutical has received FDA approval for the abbreviated new drug application of Glatiramer Acetate Injection, which is expected to enhance the company's product pipeline in overseas markets and expand its presence in the U.S. pharmaceutical market [2] Group 1 - The approval of Glatiramer Acetate will enrich the company's overseas product pipeline [2] - The company plans to actively promote the sales of this drug in international markets [2] - This development is anticipated to positively impact the company's future performance and industry position [2]